Increasing rates and changing patterns of hospital admissions for patients with inflammatory bowel disease in Ireland: 1996 – 2001
Autor: | O. Rathore, Joseph Deasy, C Smyth, Frank E. Murray, Stephen E. Patchett, S. Bacheer Picha |
---|---|
Rok vydání: | 2005 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent Severity of Illness Index Inflammatory bowel disease Age Distribution Crohn Disease medicine Humans Registries Sex Distribution Hospitals Teaching Intensive care medicine Retrospective Studies business.industry Incidence Incidence (epidemiology) Inflammatory Bowel Diseases General Medicine Length of Stay Middle Aged medicine.disease Combined Modality Therapy Ulcerative colitis digestive system diseases Infliximab Hospitalization Survival Rate Colitis Ulcerative Female business Ireland medicine.drug |
Zdroj: | Irish Journal of Medical Science. 174:28-32 |
ISSN: | 1863-4362 0021-1265 |
Popis: | The inflammatory bowel diseases require frequent hospital visits. The literature suggests that the incidence of IBD may be increasing.To investigate the pattern of admissions of patients with inflammatory bowel disease (IBD) to hospital over a five-year period (between 1996 and 2001).We obtained national data regarding admission rates for patients with IBD from the Economic and Social Research Institute (ESRI) during the years 1996 and 2001. Local data were gathered from the Hospital In-Patient Enquiry (HIPE) scheme for the same years.Over this five-year period, there has been a substantial increase in the rate of admission with IBD (58% for Crohn's disease and 25% for ulcerative colitis), in particular in the number of day-case admissions for patients with Crohn's disease (125%). There has been little change in the number of patients undergoing surgery for their disease (Crohn's disease; 24% vs 20% and Ulcerative colitis; 17% vs 16.6%) and in the length of hospital stay.Despite an increase in the rate of admission with IBD, there has been little change in the rates of surgical intervention and length of stay. The most dramatic increase was seen in the day-case admissions for patients with Crohn's disease and may reflect the use of anti-TNFalpha (infliximab) in the treatment of this disease. |
Databáze: | OpenAIRE |
Externí odkaz: |